Mifepristone 1200 mg daily + Placebo
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-resistant PTSD
Conditions
Treatment-resistant PTSD
Trial Timeline
Nov 15, 2024 → Nov 15, 2026
NCT ID
NCT06689254About Mifepristone 1200 mg daily + Placebo
Mifepristone 1200 mg daily + Placebo is a phase 2 stage product being developed by Corcept Therapeutics for Treatment-resistant PTSD. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06689254. Target conditions include Treatment-resistant PTSD.
What happened to similar drugs?
0 of 2 similar drugs in Treatment-resistant PTSD were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06689254 | Phase 2 | Recruiting |
Competing Products
6 competing products in Treatment-resistant PTSD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection | Novartis | Phase 2 | 35 |
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 35 |
| Lu AF35700 + Risperidone + Olanzapine | Lundbeck | Phase 3 | 29 |
| GH001 + Placebo | GH Research | Phase 2 | 29 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 25 |
| Evenamide 15 mg bid + Placebo | Newron Pharmaceuticals | Phase 3 | 37 |